Natera, Inc. (NASDAQ:NTRA) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
On May 9, 2017, Natera, Inc. (Natera) issued a press release
announcing its results for its first quarter ended March 31, 2017
and provided a related investor presentation. A copy of the press
release and a copy of the investor presentation are furnished
herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this
Current Report on Form 8-K and are incorporated herein by
reference.
The information in this Current Report on Form 8-K and the
accompanying Exhibit 99.1 and Exhibit 99.2 shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, regardless of any
general incorporation language in such filing, unless expressly
incorporated by reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
| 99.1 | Press Release dated May 9, 2017. | |
| 99.2 | Investor Presentation. | |
About Natera, Inc. (NASDAQ:NTRA)
Natera, Inc. is a diagnostics company. The Company’s product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother’s blood and a blood sample from the alleged father(s). Natera, Inc. (NASDAQ:NTRA) Recent Trading Information
Natera, Inc. (NASDAQ:NTRA) closed its last trading session down -0.22 at 9.16 with 155,254 shares trading hands.
